Clinical Trials Directory

Trials / Recruiting

RecruitingNCT04755764

Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy

The Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by Impedance Cardiography in Early Pregnancy

Status
Recruiting
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Marshall University · Academic / Other
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. Patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.

Detailed description

When a patient presents to the Maternal Hypertension Center at Cabell Huntington Hospital, she will receive a non-invasive hemodynamic assessment via the NICaS system as per usual protocol. The NICaS system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. In typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). The medication to be given to each subject will be based on their hemodynamics. Specifically, nifedipine will be given for a mean arterial pressure \>100 and a beta blocker will be given for a cardiac output \>8 l/min. The patients will be asked to return in one week for repeat ICG measurement.

Conditions

Interventions

TypeNameDescription
DRUGLabetalolBeta blocker
DRUGAtenololBeta blocker
DRUGNifedipineCalcium channel blocker

Timeline

Start date
2021-03-03
Primary completion
2025-12-01
Completion
2025-12-01
First posted
2021-02-16
Last updated
2025-05-13

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04755764. Inclusion in this directory is not an endorsement.